Abivax Clears Key Safety Review for Lead Drug Candidate

Abivax's obefazimod clears key safety review for UC, with €530M cash extending runway to 2027. Topline Phase 3 data expected Q2 2026.

The clinical development program for Abivax's flagship therapeutic, obefazimod, has passed a significant regulatory checkpoint. An independent safety committee's review of Phase 3 trial data for ulcerative colitis treatment identified no new risks, keeping the biotech firm on track to release final study results this summer.

Financial Runway Extended Through 2027

Alongside this clinical progress, recently filed annual reports with France's AMF and the U.S. SEC provide a clear picture of the company's financial health. As of the end of 2025, Abivax held cash, cash equivalents, and short-term investments totaling €530.4 million. Despite reporting an annual net loss of €336.1 million for 2025, management states this liquidity secures funding through the fourth quarter of 2027.

The company is also bolstering its leadership team in preparation for a potential product launch. Michael Nesrallah has been appointed to the newly created role of Chief Commercial Officer, where he will lead commercial strategy and preparation efforts.

Independent Committee Confirms Safety Profile

This positive safety assessment came from the independent Data Safety Monitoring Board (DSMB), which completed its planned review of the ABTECT-UC study on March 18. The analysis encompassed all randomized patients, with nearly 90% having already completed the 44-week maintenance phase of the trial. The DSMB raised no concerns, confirming the safety profile of the drug candidate. Obefazimod is designed to modulate the immune response in chronic inflammatory diseases.

Upcoming Catalyst: Topline Data Release

Investor attention now shifts to the next major milestone scheduled for the end of the second quarter of 2026. Abivax plans to announce the topline results from the maintenance study at that time. Successful data from this trial would form the foundation for a subsequent marketing authorization application to treat ulcerative colitis, a form of inflammatory bowel disease.

The clearance of this safety review without issues supports the continued advancement of the obefazimod program, representing a critical step toward its potential commercialization.